InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Enrolls First Patients in ALIGN-ACS Pilot Study for Heart Attack Detection
March 5, 2026
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the enrollment of the first patients in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection. The first patients were enrolled by Prof. Dr. Vladan Vukcevic at the University Clinical Center of Serbia in Belgrade, marking a key step toward […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Schedules March 12 Conference Call to Review Q4 and Full-Year 2025 Results
March 5, 2026
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through advanced cardiac insights, will host a conference call at 4:30 p.m. Eastern time on March 12, 2026, to discuss its financial results for the fourth quarter and full year ended Dec. 31, 2025, and provide updates on key strategic growth initiatives, including the […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Announces Commercial Partnership With ClearCardio as First Customer and Strategic Investor
March 4, 2026
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through advanced cardiac insights, announced a commercial partnership with ClearCardio(TM), a preventive cardiology practice serving thousands of patients through heart health screening and personalized prevention programs. ClearCardio will serve as HeartBeam’s first commercial customer and plans to make an investment in the company, […]
HeartBeam Inc. (NASDAQ: BEAT) Upgraded to Buy as New Joseph Gunnar Report Raises Price Target on Commercialization Momentum
March 3, 2026
Equity research reports often serve as important barometers of shifting sentiment, offering investors detailed analysis of a company’s strategy, risks and growth potential. In a new research note, Joseph Gunnar & Co. upgraded HeartBeam (NASDAQ: BEAT) from Hold to Buy and raised its 12-month price target to $4 from $1, citing regulatory progress and the […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Showcased for Advancing Innovative ECG Platform
February 19, 2026
HeartBeam (NASDAQ: BEAT) was featured among a select group of medical device companies in a January industry roundup highlighting recent U.S. Food and Drug Administration (“FDA”) clearances and approvals across the sector. An article discussing this reads, “The recognition underscores HeartBeam’s progress as it advances a novel approach to cardiac diagnostics through its HeartBeam System, […]
HeartBeam Inc. (NASDAQ: BEAT) Highlighted Among Medical Device Innovators as FDA Clearances Set Tone for New Year
February 12, 2026
HeartBeam (NASDAQ: BEAT) was recently recognized among a select group of medical device companies featured in a January industry roundup highlighting recent U.S. Food and Drug Administration (“FDA”) clearances and approvals across the sector. The recognition underscores HeartBeam’s progress as it advances a novel approach to cardiac diagnostics through its HeartBeam System, a cable-free, high-fidelity […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Appoints Bryan Humbarger as Chief Commercial Officer
January 22, 2026
HeartBeam (NASDAQ: BEAT), a medical technology company focused on advancing cardiac care through actionable cardiac insights, announced the appointment of Bryan Humbarger as chief commercial officer, effective Jan. 22, 2026. In the newly created role, Humbarger will lead commercial strategy and execution across key growth initiatives, including the limited launch of the recently cleared HeartBeam System for arrhythmia […]
InvestorNewsBreaks – FDA Clearance for HeartBeam Inc. (NASDAQ: BEAT) Highlighted in Medical Device Approvals Roundup
January 9, 2026
HeartBeam (NASDAQ: BEAT) was among the medical device companies highlighted in a Jan. 8 report by Modern Healthcare by Lauren Dubinsky that outlined FDA clearances and approvals across the medical device sector. HeartBeam’s 12-lead electrocardiogram synthesis software was cleared Dec. 8 to assess arrhythmias by converting heart signal data captured from 3 dimensions using the company’s portable, non-invasive recorder into a standard […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Attend JP Morgan 2026 Annual Healthcare Conference
January 5, 2026
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through advanced cardiac insights, announced that it will attend the JP Morgan 2026 Annual Healthcare Conference taking place Jan. 12–15, 2026, at the Westin St. Francis Hotel in San Francisco, where Chief Executive Officer Robert Eno and Chief Financial Officer Timothy Cruickshank will […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Ranks Second Worldwide in 12-Lead ECG Innovation
December 17, 2025
HeartBeam (NASDAQ: BEAT), a medical-technology company developing advanced electrocardiogram solutions, was featured in a recent article that discussed its recognition as a Global IP and Technology Leader in Portable Cardiac Diagnostics by PatentVest’s “Total Cardiac Intelligence” report. “The company ranked second worldwide in 12-lead ECG innovation among 243 firms analyzed, trailing only GE Healthcare. The […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Secures FDA 510(k) Clearance for 12-Lead ECG Synthesis Software Following Successful Appeal
December 9, 2025
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through personalized insights, received FDA 510(k) clearance for its 12-lead ECG synthesis software for arrhythmia assessment after successfully appealing a prior NSE determination. The patented cable-free technology captures cardiac electrical signals in three non-coplanar dimensions to generate a synthesized 12-lead ECG that can […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Outlines Regulatory Strategy After NSE Decision on ECG Synthesis Software
December 1, 2025
HeartBeam (NASDAQ: BEAT), a medical technology company developing personalized cardiac-care insights, detailed its strategy following receipt of a Not Substantially Equivalent decision for its 510(k) submission covering its 12-lead ECG Synthesis Software. The Company has been in active discussions with FDA review staff, which have signaled willingness to work toward a constructive resolution. HeartBeam said […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Poised in the Future of Cardiac Care with Breakthrough Technology
November 19, 2025
HeartBeam (NASDAQ: BEAT) is on the verge of transforming how atrial fibrillation (“AF”) is detected and managed with its cable-free ECG technology. A recent article discussing this reads, “HeartBeam has developed a credit card-sized device and proprietary synthesis software that can capture heart signals in three dimensions and convert them into a full synthesized 12-lead […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Reports Q3 2025 Results as FDA Review Nears Completion and Commercial Readiness Accelerates
November 14, 2025
HeartBeam (NASDAQ: BEAT) reported third-quarter 2025 results and highlighted continued progress toward commercialization of its 12-lead ECG synthesis software, now in the final stage of FDA 510(k) review with anticipated clearance by year end. The company is advancing commercial readiness, including a new partnership with HeartNexus for 24/7 cardiologist review services, alongside new scientific data […]
HeartBeam Inc. (NASDAQ: BEAT) Advances Remote Cardiac Diagnostics with HeartNexus Partnership
November 13, 2025
HeartBeam (NASDAQ: BEAT), a medical-technology company developing next-generation cardiac diagnostics via its patented 12-Lead ECG synthesis software, has announced a strategic collaboration with HeartNexus (https://ibn.fm/yyz1i). The partnership will expand access to cardiologist-level ECG insights for arrhythmia assessment anytime, anywhere. Cardiovascular disease remains the leading cause of mortality worldwide, responsible for an estimated 17.9 million deaths […]
HeartBeam Inc. (NASDAQ: BEAT) Recognized as a Top Global Innovator in Portable ECG Technology
November 11, 2025
HeartBeam (NASDAQ: BEAT), a medical-technology company developing advanced electrocardiogram solutions for remote cardiac care, has been recognized as a Global IP and Technology Leader in Portable Cardiac Diagnostics by PatentVest’s “Total Cardiac Intelligence” report (https://ibn.fm/ZuLCr). The company ranked second worldwide in 12-lead ECG innovation among 243 firms analyzed, trailing only GE Healthcare. The recognition highlights HeartBeam’s growing […]
HeartBeam Inc. (NASDAQ: BEAT) Advances Toward Commercialization of Groundbreaking ECG System
November 6, 2025
In the world of heart health, palpitations are common, with atrial fibrillation (“AF”) being one of the most typical sustained arrhythmias in adults (https://ibn.fm/8TSNY). HeartBeam (NASDAQ: BEAT) is on the verge of transforming how AF is detected and managed with its breakthrough, cable-free ECG technology (https://ibn.fm/B16MX). “Most palpitations occur during normal sinus rhythm, and AF […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Initiated With Buy Rating and $4 Price Target by Roth Capital
November 5, 2025
HeartBeam (NASDAQ: BEAT) has been initiated with a Buy rating and $4 price target by Roth Capital Partners, which highlighted the company’s near-term catalyst of expected FDA clearance for its groundbreaking 12-lead ECG synthesis software. The report cites BEAT’s compact, credit card-sized, cable-free device capable of synthesizing a full 12-lead ECG as a breakthrough in […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Schedules Third Quarter 2025 Conference Call for Nov. 13
October 30, 2025
HeartBeam (NASDAQ: BEAT), a medical technology company transforming cardiac care through personalized insights, will hold a conference call on Thursday, Nov. 13, 2025, at 4:30 p.m. ET to discuss its third quarter results for the period ended Sept. 30, 2025. The Company will also provide updates on regulatory progress, commercial-readiness activities, and upcoming milestones. A […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Partners with HeartNexus to Deliver 24/7 Remote Cardiology Services and Real-Time ECG Interpretation
October 28, 2025
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through personalized insights, today announced a partnership with HeartNexus Inc., a network of board-certified cardiologists specializing in cardiac test interpretation, peer consultations, and telemedicine visits. The collaboration enables HeartBeam to offer 24/7 cardiology reader services for patients experiencing cardiac symptoms outside traditional care […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Combining Portability and Precision to Redefine Future of Cardiac Care
October 16, 2025
HeartBeam (NASDAQ: BEAT) was featured in a recent article that discussed its development of a portable, credit-card-sized device and proprietary software capable of capturing heart signals in three non-coplanar dimensions and reconstructing those signals into a full synthesized 12-lead ECG. “The importance of such innovation is underscored by the widespread impact of heart disease, such […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) on the Beat of Cardiac Innovation
October 8, 2025
HeartBeam (NASDAQ: BEAT) is on the verge of revolutionizing cardiac diagnostics with its groundbreaking ECG technology. A recent article discussing this reads, “HeartBeam plans to initiate commercialization immediately upon receiving FDA clearance. The company’s vision is to empower patients and healthcare providers by offering a portable, cable-free ECG solution that combines clinical-grade accuracy with ease […]
HeartBeam Inc. (NASDAQ: BEAT) Validates ECG Technology with Strong Results in Pivotal Study
October 7, 2025
Early and accurate detection of heart rhythm problems can mean the difference between life-saving intervention and a missed opportunity, which is why new advances in cardiac diagnostics carry such weight. HeartBeam (NASDAQ: BEAT) has reported promising results from its pivotal VALID-ECG study (https://ibn.fm/BDiIa), demonstrating that its synthesized 12-lead ECG technology delivers a strong correlation with […]
ROTH to Host 4th Annual Healthcare Opportunities Conference on October 9 in New York City
October 1, 2025
NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) — via IBN — ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to announce it will host the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Metropolitan Club, New York City, NY. The Annual ROTH Healthcare Opportunities Conference will once again bring together C-suite executives from innovative public […]
InvestorNewsBreaks – HeartBeam Inc.’s (NASDAQ: BEAT) ECG System Offers Real-Time Cardiac Insights
September 26, 2025
HeartBeam (NASDAQ: BEAT) is positioned amid limitations of traditional 12-lead electrocardiogram (“ECG”) systems, often including cumbersome setups and restricted accessibility. The company “is addressing these challenges by developing the HeartBeam System, the first cable-free, high-fidelity ECG system that captures the heart’s electrical signals from three distinct directions and synthesizes the signals into a 12-lead ECG, enabling […]
InvestorNewsBreaks – HeartBeam Inc.’s (NASDAQ: BEAT) First-of-Its-Kind Cable-Free ECG Offers Multi-Angle Signal Capture
September 22, 2025
As clinicians increasingly recognize the value of accurate at-home electrocardiogram (“ECG”) capture, HeartBeam (NASDAQ: BEAT) is positioned at the forefront of this transformation. The company’s FDA-cleared HeartBeam System is the first cable-free ECG device that captures the heart’s signals from three distinct directions and is designed to be a groundbreaking solution for at-home detection and […]
HeartBeam Inc. (NASDAQ: BEAT) Prepares Innovative ECG Technology for Commercial Launch
September 12, 2025
In its most recent quarterly update, HeartBeam (NASDAQ: BEAT) is reporting that the company is on the verge of revolutionizing cardiac diagnostics with its groundbreaking ECG technology. The company is actively preparing for FDA 510(k) clearance of its innovative 12-lead ECG synthesis software for arrhythmia assessment while executing comprehensive commercial readiness plans for a technology […]
HeartBeam Inc. (NASDAQ: BEAT) Advances Power of ECG with High-Fidelity At-Home Heart-Monitoring System
September 10, 2025
For decades, the traditional 12-lead electrocardiogram (“ECG”) has been the gold standard in cardiac diagnostics, including arrhythmia assessment, offering a comprehensive assessment of the heart’s electrical activity. However, traditional 12-lead ECG systems often come with limitations such as cumbersome setups and restricted accessibility. HeartBeam (NASDAQ: BEAT) is addressing these challenges by developing the HeartBeam System, the first […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Reports Study Showing Comparable Accuracy Between HeartBeam System and Standard 12-Lead ECG in Detecting Arrhythmias
September 8, 2025
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care with personalized insights, announced study results showing no significant differences in detecting atrial fibrillation, atrial flutter and sinus rhythm when its deep learning algorithms were applied to the HeartBeam System versus standard 12-lead ECGs. Data from 201 patients, presented at HRX Live 2025 […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Profiled on Credit-Card-Sized Device That Synthesizes 12-Lead ECG
August 28, 2025
HeartBeam (NASDAQ: BEAT) is the focus of a piece by Susan Shepard for MD+DI detailing how the company’s credit-card-sized ECG device captures three-dimensional signals to synthesize a full 12-lead output. Cleared by the FDA last December, the portable system is designed for patients to carry in a wallet or purse for on-demand readings, providing hospital-level […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Present at Three September Investor Conferences
August 28, 2025
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, announced that CEO Robert Eno and CFO Timothy Cruickshank will attend the MDB Investor Summit 2025, HRX Live 2025, and the H.C. Wainwright 27th Annual Global Investment Conference in September. At these events, the executives will meet with partners and investors while providing […]
HeartBeam Inc. (NASDAQ: BEAT) Advances Patient Convenience with At-Home ECG Technology
August 27, 2025
Clinicians are increasingly recognizing the value of accurate at-home electrocardiogram (“ECG”) capture, a development that is shaping the future of cardiac care. HeartBeam (NASDAQ: BEAT) is positioned at the forefront of this transformation with its FDA-cleared HeartBeam System, the first cable-free ECG device that captures the heart’s signals from 3 distinct directions and is designed […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Paves Way to Redefine Cardiac Care
August 26, 2025
HeartBeam (NASDAQ: BEAT) has secured foundational clearance from the U.S. Food and Drug Administration (“FDA”) for its patented HeartBeam system. “The first cable-free, high-fidelity ECG device that captures the heart’s electrical activity from three distinct directions, the HeartBeam system enables patients and physicians to access critical arrhythmia data outside traditional clinical settings,” reads a recent […]
InvestorNewsBreaks – HeartBeam Inc.’s (NASDAQ: BEAT) IP Momentum Continues with New Patents Advancing 3D ECG Technology
August 21, 2025
HeartBeam (NASDAQ: BEAT) recently secured two new U.S. patents that significantly enhance its intellectual property portfolio and strengthen its position in cardiac monitoring technology. Focused on delivering powerful, personalized insights into heart health through its innovative 3D ECG platform, the company now holds more than 20 U.S. and international patents, with additional applications pending. “HeartBeam’s […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Reports Q2 2025 Results, Advances Toward FDA Clearance and Commercial Launch
August 14, 2025
HeartBeam (NASDAQ: BEAT), a medical technology company developing personalized cardiac care solutions, reported financial and operational results for the quarter ended June 30, 2025. The company said it remains on track to receive FDA 510(k) clearance for its 12-lead ECG synthesis software for arrhythmia assessment by year-end, following positive pivotal study results showing 93.4% diagnostic […]
HeartBeam Inc. (NASDAQ: BEAT) FDA-Cleared System Provides Momentum as Company Moves to Innovate Cardiac Care
August 6, 2025
Foundational clearance from the U.S. Food and Drug Administration (“FDA”) for its patented HeartBeam system has proved pivotal for HeartBeam (NASDAQ: BEAT), a cardiac technology company focused on transforming the cardiac-care space (https://ibn.fm/0TAG4). The first cable-free, high-fidelity ECG device that captures the heart’s electrical activity from three distinct directions, the HeartBeam system enables patients and […]
HeartBeam Inc.’s (NASDAQ: BEAT) Two New U.S. Patents Power Next Generation of Cardiac Diagnostics
August 5, 2025
HeartBeam (NASDAQ: BEAT), a cardiac technology company, has secured two new U.S. patents that significantly enhance its intellectual property portfolio and strengthen its position in cardiac monitoring technology (https://ibn.fm/6xni4). The company, focused on delivering powerful, personalized insights into heart health through its innovative 3D ECG platform, now holds more than 20 U.S. and international patents, […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Schedules Aug. 13 Call to Discuss Q2 Results and Provide Business Updates
July 30, 2025
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care with personalized insights, will hold a conference call Aug. 13, 2025, at 4:30 p.m. Eastern to discuss second-quarter results for the period ended June 30, 2025. The company will also provide updates on regulatory initiatives, commercial-readiness activities and anticipated milestones. CEO Robert Eno […]
InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Wins 2025 Innovation Award for Remote Cardiac Diagnostics
July 22, 2025
HeartBeam (NASDAQ: BEAT), a medical technology company advancing personalized cardiac care, has received the Innovation Award in Remote Cardiac Diagnostics from the 2025 Medical Device Network Excellence Awards. The honor recognizes HeartBeam’s FDA-cleared 3D ECG technology, which enables clinical-grade arrhythmia diagnostics in non-clinical settings via a compact, cable-free device. The synthesized 12-lead ECG software is […]
InvestorNewsBreaks – Why HeartBeam Inc. (NASDAQ: BEAT) Is ‘One to Watch’
July 8, 2025
HeartBeam (NASDAQ: BEAT) is a medical technology company developing a groundbreaking solution for at-home detection and monitoring of cardiac conditions. “HeartBeam’s vision is to redefine cardiac care by enabling early detection, proactive monitoring, and informed clinical decisions outside the confines of a traditional medical setting. Its patented approach not only delivers similar, but not identical, […]